Company Overview of Cerecor, Inc.
Cerecor, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pharmaceuticals. The company focuses on human brain and nervous system. Its products include translational medicines, products for cough, and inhibitors for schizophrenia. The company was incorporated in 2011 and is based in Baltimore, Maryland.
2400 Boston Street
Baltimore, MD 21224
Founded in 2011
Key Executives for Cerecor, Inc.
Co-Founder, Chief Executive Officer and Director
Founder and Chairman of Scientific Advisory Board
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Cerecor, Inc. Key Developments
Cerecor Inc. Announces Board Changes
May 29 15
Cerecor Inc. announced that it has appointed Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs. Dr. Marcus has more than 20 years of experience in the development of neuroscience drugs at both Spinifex and Bristol-Myers Squibb (BMS). In addition, the company has appointed Uli Hacksell, PhD, as Chairman of the Board of Directors. Dr. Hacksell was most recently CEO of ACADIA Pharmaceuticals Inc. Dr. Hacksell is replacing Sol Barer, PhD, who stepped down as the Chairman and as a member of the company’s board of directors in April 2015. Dr. Marcus was most recently the Chief Medical Officer at Spinifex.
Cerecor, Inc. Provides Update on CERC-301 Development in Major Depressive Disorder
Mar 20 15
Cerecor, Inc. announced the results of an exploratory inpatient pharmacokinetic/pharmacodynamic (PK/PD) study and the results of a Phase 2 outpatient efficacy study of CERC-301 for the adjunctive treatment of patients with major depressive disorder (MDD), who had recently experienced suicidal ideation. The PK/PD study provided evidence of safety and tolerability at daily doses up to 20mg, providing the basis for future efficacy studies at doses greater than 8mg. In the Phase 2 study, CERC-301 was administered daily at a dose of 8mg for 28 days and did not meet its primary endpoint of a change in the Hamilton Depression Rating Scale at day 7. CERC-301 is an oral, selective NMDA receptor subunit (NR2B) antagonist, which is thought to provide a rapid onset of antidepressant effect without the undesirable intoxication and hallucinations of non-selective NMDA receptor antagonists. In both studies, CERC-301 was well-tolerated and did not induce these untoward effects. The 135 patient, placebo-controlled Phase 2 study was designed to assess CERC-301 as adjunctive treatment for patients with MDD, who had failed to adequately respond to current selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) treatment, had recent active suicidal ideation, and were deemed appropriate for an out-patient study. The safety and efficacy of 8mg of CERC-301 per day were evaluated over 28 days of treatment, with the primary endpoint of the change in the Hamilton Depression Rating Scale at day 7. In the PK/PD study, 48 patients were enrolled, and CERC-301 was well-tolerated at doses up to 20mg per day. The company plans to initiate the next Phase 2 efficacy study, evaluating a higher dose and revised dosing regimen of CERC-301 in the second half of 2015.
Cerecor Purchases Rights from Eli Lilly to Develop LY2456302
Feb 25 15
Cerecor reported that it has acquired exclusive, worldwide rights from Eli Lilly and Company to develop and commercialize LY2456302, a Phase 2-ready, potent and selective kappa opioid receptor antagonist. KORs are believed to play a key role in modulating stress, mood and addictive disorders. Research also suggests that selective KOR antagonists can block both the physical and emotional symptoms of nicotine withdrawal. CERC-501 was discovered and developed by Lilly for the treatment of co-occurring disorders, defined as a patient having one or more disorders relating to substance abuse combined with one or more mental health disorders. In Phase 1 clinical studies, CERC-501 was well tolerated, penetrated the blood-brain barrier and demonstrated target engagement, as shown through PET (positron emission tomography) imaging.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 11, 2014